Home » Specialist » Today announced results of preclinical research on ponatinib.

The data also display that ponatinib potently inhibits the activity of most four FGFRs at clinically achievable medication levels and provide strong rationale for ponatinib’s evaluation in sufferers with FGFR-driven cancers. .. ARIAD’s ponatinib potently inhibits all FGFRs abnormally expressed in multiple cancers ARIAD Pharmaceuticals, Inc. today announced results of preclinical research on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four users of the fibroblast development factor receptor category of tyrosine kinases that are abnormally expressed in multiple cancers.A 4th line of breast cancers cells – representing the most intense form of the condition – was also studied in a mouse breast tumor model, followed by treatment with AAV2. Preliminary results show the destruction of the tumors in the mice, and researchers will report the findings of those mouse studies soon.

16th WCTOH announces new speakers, programme and scientific highlights The World Meeting on Tobacco or Health announced today that South Africa Minister of Health Dr Aaron Motsoaledi will address conference delegates throughout a ministerial plenary on the linkages between tobacco use and non-communicable diseases.